The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection

Powrózek, Tomasz; Kuźnar-Kamińska, Barbara; Dziedzic, Marcin; Mlak, Radosław; Batura‐Gabryel, Halina; Sagan, Dariusz; Krawczyk, Paweł; Milanowski, Janusz; Małecka‐Massalska, Teresa

doi:10.1016/j.prp.2017.09.011

Cited by 22 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along the same lines, studies have shown that precursors of certain miRNAs, such as miRNA-944 and miRNA-3662, can differentiate early ADC from SCC, thus aiming to label pri-miRNAs as a novel class of lung cancer markers. In this regard, it was observed that pri-miRNA-3662 was highly expressed in ADC patients in stages I and II, while the expression of pri-miRNA-944 was higher in SCC patients in stages I and II [181]. On the other hand, in SCLC, Nishikawa et al showed that miR-375 was significantly increased in SCLC cell lines as opposed to those of different histologic types when they examined the miRNA expression profiles on lung cell lines [182].…”

Section: Mirnas In Distinguishing Cancer Subtypesmentioning

confidence: 95%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

757

510

View full text Add to dashboard Cite

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs with the main roles of regulating mRNA through its degradation and adjusting protein levels. In recent years, extraordinary progress has been made in terms of identifying the origin and exact functions of miRNA, focusing on their potential use in both the research and the clinical field. This review aims at improving the current understanding of these molecules and their applicability in the medical field. A thorough analysis of the literature consulting resources available in online databases such as NCBI, PubMed, Medline, ScienceDirect, and UpToDate was performed. There is promising evidence that in spite of the lack of standardized protocols regarding the use of miRNAs in current clinical practice, they constitute a reliable tool for future use. These molecules meet most of the required criteria for being an ideal biomarker, such as accessibility, high specificity, and sensitivity. Despite present limitations, miRNAs as biomarkers for various conditions remain an impressive research field. As current techniques evolve, we anticipate that miRNAs will become a routine approach in the development of personalized patient profiles, thus permitting more specific therapeutic interventions.Biogenesis of miRNA begins in the nucleus, where the transcription of its precursor, primary miRNA or pri-miRNA takes place under the influence of RNA polymerases II and III [11,12]. The resulting molecule is a hairpin-like structure, which contains a loop at one end [11]. This primordial mi-RNA precursor that is usually made up of hundreds of nucleotides is then processed consecutively by two RNase III enzymes [13][14][15]. The first enzyme to act upon the pri-miRNA, which still resides in the nucleus, is called Drosha or DCGR8, and turns it into a new hairpin-like structure of approximately 70 nucleotides, the Precursor-miRNA or pre-miRNA. The latter is then transported to the cytoplasm, with the help of Exportin-5, where it is cleaved again by the Ago2/Dicer complex leading to the short, mature miRNA double strands [16].Further on, one of the strands, usually known as the guide strand, will be integrated into the RNA-induced silencing complex (RISC), while the other one, known as the passenger strand, is going to be degraded, even though in some occasions it has been found to be also functional [17]. In most cases, the strand that contains the less stable 5 end or a uracil at the beginning is more likely to be selected as the guide strand [18][19][20]. In those situations, where the passenger strand is not degraded and both get incorporated into the miRISC complex, the mature miRNA in the guide strand will be the dominant one [21,22].The main role of miRNA in the human body is gene regulation [23] by mediating the degradation of mRNA and also by regulating transcription and translation through canonical and non-canonical mechanisms [4]. The canonical mechanism means that the miRISC complex containing the miRNA guide strand is exerting its action by binding to the targ...

show abstract

Section: Mirnas In Distinguishing Cancer Subtypesmentioning

confidence: 95%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

757

510

View full text Add to dashboard Cite

show abstract

“…Serum miR-126-3p, miR-182-5p, miR-183-5p, and miR-210-3p were also found to possess early detective value for NSCLC patients, exhibiting similar sensitivity and specificity with traditional tumor marker CEA [ 20 ]. Two miRNA precursors, pri-miR-944 and pri-miR-3662, were also capable of distinguishing NSCLC at stages I–IIIA [ 21 ]. Significantly decreased levels of miR-125a-3p were observed in plasma exosomes of colon cancer patients [ 22 ], as well as increased levels of miR-23a-3p, miR-27a-3p, miR-142-5p, and miR-376c-3p in serum [ 23 ].…”

Section: Potential Clinical Application Of Circulating Mirnasmentioning

confidence: 99%

Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage

et al. 2018

View full text Add to dashboard Cite

MicroRNAs are endogenous single-stranded non-coding small RNA molecules that can be secreted into the circulation and exist stably. They usually exhibit aberrant expression under different physiological and pathological conditions. Recently, differentially expressed circulating microRNAs were focused on as potential biomarkers for cancer screening. We herein review the role of circulating microRNAs for cancer diagnosis, tumor subtype classification, chemo- or radio-resistance monitoring, and outcome prognosis. Moreover, circulating microRNAs still have several issues hindering their reliability for the practical clinical application. Future studies need to elucidate further potential application of circulating microRNAs as specific and sensitive markers for clinical diagnosis or prognosis in cancers.

show abstract

“…Recently, miRNA appeared to be valuable diagnostic candidate biomarkers which were employed for the diagnosis of NSCLC in early stages . A diagnostic test based on miRNA‐944 and miRNA‐3662 showed 75.7% sensitivity and 82.3% specificity (AUC = 0.898) in distinguishing NSCLC from healthy individuals . In addition, a panel of CDO1 , HOXA9, AJAP1 , PTGDR , UNCX , and MARCH11 methylation could be potential biomarkers for early detection of NSCLC with high sensitivity and specificity .…”

Section: Discussionmentioning

confidence: 99%

“…35 A diagnostic test based on miRNA-944 and miRNA-3662 showed 75.7% sensitivity and 82.3% specificity (AUC = 0.898) in distinguishing NSCLC from healthy individuals. 36 In addition, a panel of CDO1, HOXA9, AJAP1, PTGDR, UNCX, and MARCH11 methylation could be potential biomarkers for early detection of NSCLC with high sensitivity and specificity. 37 And frequent simultaneous methylation of DLEC1, ITGA9, and MLH1 in more than 50% NSCLC patients indicated the possibility of considering them as a panel of epigenetic markers in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Aberrant methylation of mutL homolog 1 is associated with increased risk of non‐small cell lung cancer

Chen

Zhou

et al. 2017

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection

Cited by 22 publications

References 19 publications

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage

Aberrant methylation of mutL homolog 1 is associated with increased risk of non‐small cell lung cancer

Contact Info

Product

Resources

About